Bosutinib

Generic Name: Bosutinib

Brand Names: Bosulif

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₉Cl_₂N_₅O_₃

CAS Number: 380843-75-4

Unique Ingredient Identifier: 5018V4AEZ0

Background: Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion prote...

Indication: 用于治疗对既往治疗无效的慢性、加速期或急变期Ph+的慢性粒细胞白血病（CML）患者。

Associated Conditions: Accelerated Phase Chronic Myelogenous Leukemia (CML), Chronic Phase Chronic Myeloid Leukemia, Blast phase Chronic myeloid leukemia

Associated Therapies: -

Clinical Trials

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Phase 1

Active, not recruiting

Conditions: Metastatic Breast Cancer
Hormone Receptor Positive Breast Cancer
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Interventions: Drug: Palbociclib
Drug: Bosutinib
Drug: Fulvestrant

First Posted Date: 2019-02-26

Last Posted Date: 2023-12-21

Lead Sponsor: Georgetown University

Target Recruit Count: 19

Registration Number: NCT03854903

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis

Phase 2

Recruiting

Conditions: Chronic Myeloid Leukemia

Interventions: Drug: Bosutinib
Drug: Ropeginterferon

First Posted Date: 2019-02-06

Last Posted Date: 2023-04-19

Lead Sponsor: St. Olavs Hospital

Target Recruit Count: 212

Registration Number: NCT03831776

Locations: 🇩🇰
Aarhus ..., Aarhus, Denmark
🇸🇪
Göteborg ...., Göteborg, Sweden
🇸🇪
Universitetssjukhuset Linköping, Linköping, Sweden

and more 15 locations

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

Phase 2

Active, not recruiting

Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions: Drug: Bosutinib
Drug: Dasatinib
Other: Laboratory Biomarker Analysis
Drug: Nilotinib
Drug: Ruxolitinib
Drug: Imatinib

First Posted Date: 2018-08-31

Last Posted Date: 2024-07-08

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 84

Registration Number: NCT03654768

Locations: 🇺🇸
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
🇺🇸
Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
🇺🇸
Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States

and more 537 locations

Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)

Phase 2

Recruiting

Conditions: Lymphoma, Non-Hodgkin
Multiple Myeloma
Advanced Solid Tumors

Interventions: Drug: Erlotinib
Drug: Dasatinib
Drug: Axitinib
Drug: Bosutinib
Drug: Crizotinib
Drug: Nivolumab plus Ipilimumab
Drug: Olaparib
Drug: Palbociclib
Drug: Sunitinib
Drug: Temsirolimus
Drug: Trastuzumab plus Pertuzumab
Drug: Vemurafenib plus Cobimetinib
Drug: Vismodegib
Drug: Tucatinib

First Posted Date: 2017-09-29

Last Posted Date: 2024-11-12

Lead Sponsor: Canadian Cancer Trials Group

Target Recruit Count: 720

Registration Number: NCT03297606

Locations: 🇨🇦
Verspeeten Family Cancer Centre, London, Ontario, Canada
🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦
BCCA - Kelowna, Kelowna, British Columbia, Canada

and more 7 locations

Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients

Phase 2

Conditions: Chronic Myelogenous Leukaemia

Interventions: Drug: Bosulif

First Posted Date: 2017-07-02

Last Posted Date: 2017-07-02

Lead Sponsor: University of Bonn

Target Recruit Count: 127

Registration Number: NCT03205267

Locations: 🇩🇪
University Hospital Bonn, Bonn, Germany

Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia, Chronic Myelogenous

Interventions: Drug: Bosutinib

First Posted Date: 2017-04-25

Last Posted Date: 2022-05-19

Lead Sponsor: Pfizer

Target Recruit Count: 64

Registration Number: NCT03128411

Locations: 🇯🇵
Osaka City University Hospital, Osaka-City, Osaka, Japan
🇯🇵
Kindai University Hospital, Osaka-Sayama, Osaka, Japan
🇯🇵
NTT Medical Center Tokyo, Shinagawa-ku, Tokyo, Japan

and more 18 locations

Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Phase 3

Active, not recruiting

Conditions: Chronic Myelogenous Leukemia

Interventions: Drug: Asciminib
Drug: Bosutinib

First Posted Date: 2017-04-10

Last Posted Date: 2024-10-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 233

Registration Number: NCT03106779

Locations: 🇺🇸
University of Michigan Clinical Trials Office Main site., Ann Arbor, Michigan, United States
🇺🇸
Uni Of TX MD Anderson Cancer Cntr, Houston, Texas, United States
🇺🇸
University of Chicago Hospital, Chicago, Illinois, United States

and more 8 locations

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung
Peritoneal Cancer
Thymus Cancer
Mesothelioma
Thymoma
Uterine Cervical Cancer
Bladder Cancer
Ovarian Cancer

Interventions: Drug: Bosutinib
Drug: Pemetrexed

First Posted Date: 2017-01-18

Last Posted Date: 2022-06-14

Lead Sponsor: Nagla Abdel Karim

Target Recruit Count: 6

Registration Number: NCT03023319

Locations: 🇺🇸
Augusta University Georgia Cancer Center, Augusta, Georgia, United States

Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias

Phase 1

Conditions: Mild Cognitive Impairment
Dementia

Interventions: Drug: bosutinib

First Posted Date: 2016-10-03

Last Posted Date: 2022-09-28

Lead Sponsor: Neurological Associates of West Los Angeles

Target Recruit Count: 150

Registration Number: NCT02921477

Locations: 🇺🇸
Neurological Associates of West LA, Santa Monica, California, United States

Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure

Phase 2

Terminated

Conditions: Blasts Under 15 Percent of Peripheral Blood White Cells
Blasts Under 15 Percent of Bone Marrow Nucleated Cells
Blasts Under 30 Percent of Bone Marrow Nucleated Cells
Blasts Under 30 Percent of Peripheral Blood White Cells
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions: Drug: Bosutinib
Other: Laboratory Biomarker Analysis

First Posted Date: 2016-09-20

Last Posted Date: 2020-05-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 8

Registration Number: NCT02906696

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy